{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:42:32Z","timestamp":1791085352560,"version":"4.1.0"},"reference-count":15,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5,1]]},"abstract":"<jats:p>OBJECTIVE. The purpose of this research was to report results on long-term administration of dichloroacetate in 36 children with congenital lactic acidosis who participated previously in a controlled trial of this drug.<\/jats:p>\n               <jats:p>PATIENTS AND METHODS. We conducted a randomized control trial, followed by an open-label study. Data were analyzed for each patient from the time they began treatment through May 2005.<\/jats:p>\n               <jats:p>RESULTS.Subject exposure to dichloroacetate totaled 110.42 years. Median height and weight increased over time, but the standardized values declined slightly and remained below the first percentile. There were no significant changes in biochemical metabolic indices, except for a 2% rise in total protein and a 22% increase in 24-hour urinary oxalate. Both the basal and carbohydrate meal-induced rises in lactate were blunted by dichloroacetate. The median cerebrospinal fluid lactate also decreased over time. Conduction velocity decreased and distal latency increased in peroneal nerves. Mean 3-year survival for all of the subjects was 79%.<\/jats:p>\n               <jats:p>CONCLUSIONS. Oral dichloroacetate is generally well tolerated in young children with congenital lactic acidosis. Although continued dichloroacetate exposure is associated with evidence of peripheral neuropathy, it cannot be determined whether this is attributable mainly to the drug or to progression of underlying disease.<\/jats:p>","DOI":"10.1542\/peds.2007-2062","type":"journal-article","created":{"date-parts":[[2008,4,15]],"date-time":"2008-04-15T00:33:55Z","timestamp":1208219635000},"page":"e1223-e1228","source":"Crossref","is-referenced-by-count":112,"title":["Evaluation of Long-term Treatment of Children With Congenital Lactic Acidosis With Dichloroacetate"],"prefix":"10.1542","volume":"121","author":[{"given":"Peter W.","family":"Stacpoole","sequence":"first","affiliation":[{"name":"Departments of Medicine"},{"name":"Biochemistry and Molecular Biology"},{"name":"General Clinical Research Center, University of Florida, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesa R.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Departments of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Neiberger","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Carney","sequence":"additional","affiliation":[{"name":"Pediatrics"},{"name":"Neurology"},{"name":"Biomedical Engineering"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Valenstein","sequence":"additional","affiliation":[{"name":"Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Theriaque","sequence":"additional","affiliation":[{"name":"General Clinical Research Center, University of Florida, Gainesville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Shuster","sequence":"additional","affiliation":[{"name":"General Clinical Research Center, University of Florida, Gainesville, Florida"},{"name":"Epidemiology and Health Policy Research"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2008,5,1]]},"reference":[{"key":"2021120908244922700_R1","doi-asserted-by":"crossref","unstructured":"Stacpoole PW, Barnes CL, Hurbanis MD, Cannon SL, Kerr DS. Treatment of congenital lactic acidosis with dichloroacetate. Arch Dis Child.\u20081997;77(6):535\u2013541","DOI":"10.1136\/adc.77.6.535"},{"key":"2021120908244922700_R2","doi-asserted-by":"crossref","unstructured":"Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate as a treatment for MELAS: a randomized, controlled clinical trial. Neurology.\u20082006;66(3):324\u2013330","DOI":"10.1212\/01.wnl.0000196641.05913.27"},{"key":"2021120908244922700_R3","doi-asserted-by":"crossref","unstructured":"Stacpoole PW, Kerr DS, Barnes C, et al. A controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics.\u20082006;117(5):1519\u20131521","DOI":"10.1542\/peds.2005-1226"},{"key":"2021120908244922700_R4","doi-asserted-by":"crossref","unstructured":"Stickler D, Valenstein E, Neiberger RE, et al. Peripheral neuropathy in genetic mitochondrial diseases. Pediatr Neurology.\u20082006;34(2):127\u2013131","DOI":"10.1016\/j.pediatrneurol.2005.08.006"},{"key":"2021120908244922700_R5","doi-asserted-by":"crossref","unstructured":"Kaufmann P, Pascual JM, Anziska Y, et al. Nerve conduction abnormalities in patients with MELAS and the A3243G mutation. Arch Neurol.\u20082006;63(5):746\u2013748","DOI":"10.1001\/archneur.63.5.746"},{"key":"2021120908244922700_R6","doi-asserted-by":"crossref","unstructured":"Felitsyn N, Stacpoole PW, Notterpek L. Dichloroacetate causes reversible demyelination in vitro: Potential mechanism for its neuropathic effect. J Neurochem\u20083007;100(2):429\u2013436","DOI":"10.1111\/j.1471-4159.2006.04248.x"},{"key":"2021120908244922700_R7","doi-asserted-by":"crossref","unstructured":"Cornett R, James MO, Henderson GN, Cheung J, Shroads AL, Stacpoole PW. Inhibition of glutathione S-transferase zeta and tyrosine metabolism by dichloroaceate: a potential unifying mechanism for its altered biotransformation and toxicity. Biochem Biophys Res Commun.\u20081999;262(3):752\u2013756","DOI":"10.1006\/bbrc.1999.1287"},{"key":"2021120908244922700_R8","doi-asserted-by":"crossref","unstructured":"Langlois C, Jorquera R, Finegold M, Shroads AL, Stacpoole PW, Tanguay RM. Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1. Biochem Pharmacol.\u20082006;71(11):1648\u20131661","DOI":"10.1016\/j.bcp.2006.02.017"},{"key":"2021120908244922700_R9","unstructured":"Felitsyn N, Stacpoole PW, Notterpek L. Delta-aminolevulinic acid inhibits myelination by Schwann cells. Presented at Neuroscience 2007, San Diego, CA, November 3\u20137, 2007"},{"key":"2021120908244922700_R10","doi-asserted-by":"crossref","unstructured":"Stacpoole PW, Shroads AL, Felitsyn NM, Notterpek L, Calcutt NA. Mechanism of Age Dependence of Dichloroacetate-Induced Peripheral Neuropathy. Atlanta, GA: United Mitochondrial Disease Foundation; 2006:14\u201318","DOI":"10.1016\/j.mito.2006.08.042"},{"key":"2021120908244922700_R11","doi-asserted-by":"crossref","unstructured":"Curry SH, Chu PI, Baumgartner TG, Stacpoole PW. Plasma concentrations and metabolic effects of intravenous sodium dichloroacetate. Clin Pharmacol Ther.\u20081985;37(1):89\u201393","DOI":"10.1038\/clpt.1985.17"},{"key":"2021120908244922700_R12","doi-asserted-by":"crossref","unstructured":"Stacpoole PW, Henderson GN, Yan Z, Cornett R, James MO. Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab Rev.\u20081998;30(3):499\u2013539","DOI":"10.3109\/03602539808996323"},{"key":"2021120908244922700_R13","doi-asserted-by":"crossref","unstructured":"Ammini CV, Stacpoole PW. Biotransformation, toxicology and pharmacogenomics of dichloroacetate. In: Gribble GW, ed. Natural Production of Organohalogen Compounds. Vol.3\/P in the series The Handbook of Environmental Chemistry. Berlin, Springer-Verlag; 2003:215\u2013234","DOI":"10.1007\/b10453"},{"key":"2021120908244922700_R14","doi-asserted-by":"crossref","unstructured":"Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell.\u20082007;11(1):37\u201351","DOI":"10.1016\/j.ccr.2006.10.020"},{"key":"2021120908244922700_R15","doi-asserted-by":"crossref","unstructured":"Berendzen K, Theriaque D, Shuster J, Stacpoole, PW. Therapeutic potential of dichloroacetate for pyruvate dehydrogenase complex deficiency. Mitochondrion.\u20082006;6(3):126\u2013135","DOI":"10.1016\/j.mito.2006.04.001"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/5\/e1223\/1175162\/zpe005080e1223.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/5\/e1223\/1175162\/zpe005080e1223.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T02:45:27Z","timestamp":1639104327000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/121\/5\/e1223\/73409\/Evaluation-of-Long-term-Treatment-of-Children-With"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,1]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2008,5,1]]},"published-print":{"date-parts":[[2008,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-2062","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,1]]}}}